BCM
MRVI icon

Bayesian Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Bayesian Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-74,175
Closed -$643K – 962
2024
Q1 		$643K Buy
+74,175
New +$502K 0.06% 384
2022
Q3 		– Sell
-17,000
Closed -$483K – 910
2022
Q2 		$483K Sell
17,000
-15,645
-48% -$496K 0.09% 343
2022
Q1 		$1.15M Buy
32,645
+27,400
+522% +$919K 0.17% 177
2021
Q4 		$220K Buy
5,245
+949
+22% +$38.4K 0.07% 304
2021
Q3 		$211K Buy
+4,296
New +$210K 0.06% 336

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bayesian Capital Management's MRVI Position: Q2 2024 in Review

Bayesian Capital Management sold out of Maravai LifeSciences (MRVI) in Q2 2024, closing a stake of 74,175 shares — an estimated $643K sold.

Bayesian Capital Management first reported a position in MRVI in Q3 2021 and held it in 5 quarters. The position peaked at $1.15M in Q1 2022. 206 funds tracked by Wall St. Rank hold MRVI as of Q2 2024.

  • Bayesian Capital Management reported no remaining Maravai LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 74,175 Maravai LifeSciences shares in Q2 2024, an estimated $643K.
  • Bayesian Capital Management first reported a position in Maravai LifeSciences in Q3 2021 and held it in 5 quarters.
  • Bayesian Capital Management's Maravai LifeSciences position peaked at $1.15M in Q1 2022.
  • 206 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.